Navigation Links
The Huntington Study Group announces first-HD study
Date:6/21/2013

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada. The trial is sponsored by Auspex Pharmaceuticals, Inc. who is developing the drug for the treatment of Huntington disease, as well as Tourette syndrome and tardive dyskinesia.

First-HD is a randomized, double blind, placebo controlled study that examines the efficacy, safety and tolerability of a formulation of the investigational drug known as SD-809 for the treatment of chorea associated with Huntington Disease. The drug has the same mechanism of action as the FDA approved drug tetrabenazine that is used to lessen chorea in people with HD, an inherited disease that affects over 30,000 people in both the United States and Canada. HD is characterized by brain cell death that usually begins between the ages of 30 to 50. This cell loss results in motor, cognitive and behavioral signs and symptoms. Chorea, which is characterized by involuntary movements, is a hallmark of the disease.

Because SD-809 is more slowly metabolized than tetrabenazine, it provides more consistent and predictable drug levels and can be given less often than tetrabenazine. With these changes, a lower overall dose of SD-809 can be administered and it may be more convenient for persons with HD. This study will test the efficacy, safety and tolerability of a formulation of SD-809 in the management of chorea symptoms in HD patients who have not previously taken tetrabenazine. Participants will be involved in this trial for approximately 4 months.

Dr. Samuel Frank, the Principal Investigator of First-HD notes that "we are excited to work with Auspex to investigate the efficacy, safety and tolerability of this interesting and innovative new treatment for Huntington disease. We have few treatment options for Huntington disease, and only one for chorea. We hope this is a step forward in addressing this large unmet need for our patients."

There is no cost to participate in First-HD. Individuals with a diagnosis of HD who are interested in participating in First-HD should visit the HSG website: http://www.huntington-study-group.org or call toll free: 1(800) 487-7671 (North America). More information regarding this trial can also be found at http://clinicaltrials.gov


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Huntingtons Disease Linked to Reduced Cancer Risk in Study
2. Researchers restore neuron function to brains damaged by Huntingtons disease
3. Reach2HD, a Phase II study in Huntingtons disease, launched
4. Device implanted in brain has therapeutic potential for Huntingtons disease
5. Proposed drug may reverse Huntingtons disease symptoms
6. Well-known author and historian reports on progress in Huntingtons therapies
7. Human model of Huntingtons disease created from skins stem cells
8. Scientists Use Stem Cells to Mimic Huntingtons Disease
9. First Huntingtons disease center established in Washington, D.C., area
10. Cell loss in the brain relates to variations in individual symptoms in Huntingtons disease
11. NIH funds UT Dallas study on cause of Huntingtons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... Little Rock, AR (PRWEB) , ... October 13, ... ... owned firm with locations throughout Arkansas that offers insurance and financial preparation services, ... to benefit the Rock City Rescue organization. , Rock City Rescue is a ...
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... ... 2017 , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud ... and unique items from across the nation, this holiday-themed event will raise funds and ... the VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
Breaking Medicine Technology: